Uterine carcinosarcoma

Current Opinion in Oncology

Volumn 23, Issue 5, 2011, Pages 531-536

  Arend, Rebecca ^a   Doneza, Janine A ^a   Wright, Jason D ^a  

^a New York Presbyterian Columbia University Medical Center   (United States)

Author keywords

Carcinosarcoma; endometrial cancer; hysterectomy; malignant mixed mullerian tumor; uterine cancer; uterine neoplasms

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GEMCITABINE; IFOSFAMIDE; MESNA; PACLITAXEL; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROGESTERONE RECEPTOR; PROTEIN KINASE B; SOMATOMEDIN B; SOMATOMEDIN C; TOPOTECAN;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER INVASION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CARCINOSARCOMA; CHEMORADIOTHERAPY; CLINICAL FEATURE; CYTOREDUCTIVE SURGERY; HUMAN; HYSTERECTOMY; LEIOMYOSARCOMA; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MONOTHERAPY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RECURRENCE RISK; RECURRENT CANCER; SALPINGOOOPHORECTOMY; UTERUS CARCINOMA; UTERUS CARCINOSARCOMA; UTERUS SARCOMA;

CARCINOSARCOMA; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; UTERINE NEOPLASMS;

EID: 80052027169     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0b013e328349a45b     Document Type: Article

References (63)

1. Arrastia CD, Fruchter RG, Clark M, et al. Uterine carcinosarcomas: incidence and trends in management and survival. Gynecol Oncol 1997; 65:158-163. (Pubitemid 27171567)
2. Harlow BL, Weiss NS, Lofton S. The epidemiology of sarcomas of the uterus. J Natl Cancer Inst 1986; 76:399-402. (Pubitemid 16119773)
3. Cimbaluk D, Rotmensch J, Scudiere J, et al. Uterine carcinosarcoma: immunohistochemical studies on tissue microarrays with focus on potential therapeutic targets. Gynecol Oncol 2007; 105:138-144. (Pubitemid 46441450)
4. Giuntoli RL 2nd, Metzinger DS, DiMarco CS, et al. Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy. Gynecol Oncol 2003; 89:460-469. (Pubitemid 36687793)
5. Gadducci A, Sartori E, Landoni F, et al. The prognostic relevance of histological type in uterine sarcomas: a Cooperation Task Force (CTF) multivariate analysis of 249 cases. Eur J Gynaecol Oncol 2002; 23:295-299. (Pubitemid 34948043)
6. Zelmanowicz A, Hildesheim A, Sherman ME, et al. Evidence for a common etiology for endometrial carcinomas and malignant mixed mullerian tumors. Gynecol Oncol 1998; 69:253-257. (Pubitemid 28289969)
7. McCluggage WG. Uterine carcinosarcoma related to tamoxifen. Int J Gynecol Cancer 2003; 13:697-698; author reply 698.
8. Curtis RE, Freedman DM, Sherman ME, Fraumeni JF Jr. Risk of malignant mixed mullerian tumors after tamoxifen therapy for breast cancer. J Natl Cancer Inst 2004; 96:70-74. (Pubitemid 38180962)
9. Bansal N, Herzog TJ, Seshan VE, et al. Uterine carcinosarcomas and grade 3 endometrioid cancers: evidence for distinct tumor behavior. Obstet Gynecol 2008; 112:64-70.
10. Arend R, Bagaria M, Lewin SN, et al. Long-term outcome and natural history of uterine adenosarcomas. Gynecol Oncol 2010; 119:305-308.
11. Kempson RL, Hendrickson MR. Smooth muscle, endometrial stromal, and mixed mullerian tumors of the uterus. Mod Pathol 2000; 13:328-342. (Pubitemid 30207516)
12. Gonzalez Bosquet J, Terstriep SA, Cliby WA, et al. The impact of multimodal therapy on survival for uterine carcinosarcoma. Gynecol Oncol 2010; 116:419-423.
13. Kernochan LE, Garcia RL. Carcinosarcomas (malignant mixed Mullerian tumor) of the uterus: advances in elucidation of biologic and clinical characteristics. J Natl Compr Canc Netw 2009; 7:550-556.
14. Euscher E, Wei C, Ramondetta L, Broaddus R. Reverse-phase protein lysate array identified potential therapeutic targets in uterine carcinosarcoma. Supplement to Gynecologic Oncology: Abstracts Presented for the 42nd Annual Meeting of the Society of Gynecologic Oncologists 2011. Vol. 120. p. S92.
15. Amant F, Vergote I. Importance of the endometrioid carcinoma subtype and sarcomatous component in uterine carcinosarcoma. Gynecol Oncol 2004; 93:272-273; author reply 273-274.
16. Livasy CA, Reading FC, Moore DT, et al. EGFR expression and HER2/neu overexpression/amplification in endometrial carcinosarcoma. Gynecol Oncol 2006; 100:101-106. (Pubitemid 41815057)
17. Rice LW, Stone RL, Xu M, et al. Biologic targets for therapeutic intervention in endometrioid endometrial adenocarcinoma and malignant mixed mullerian tumors.AmJObstetGynecol2006;194:1119-1126;discussion1126-1128.
18. Menczer J, Kravtsov V, Levy T, et al. Expression of c-kit in uterine carcinosarcoma. Gynecol Oncol 2005; 96:210-215. (Pubitemid 39612439)
19. Menczer J, Schreiber L, Sukmanov O, et al. COX-2 expression in uterine carcinosarcoma. Acta Obstet Gynecol Scand 2010; 89:120-125.
20. Galaal K, Kew FM, Tam KF, et al. Evaluation of prognostic factors and treatment outcomes in uterine carcinosarcoma. Eur J Obstet Gynecol Reprod Biol 2009; 143:88-92.
21. Major FJ, Blessing JA, Silverberg SG, et al. Prognostic factors in early-stage uterine sarcoma. A Gynecologic Oncology Group study. Cancer 1993; 71:1702-1709. (Pubitemid 23056094)
22. Lewin SN. Revised FIGO Staging System for endometrial cancer. ClinObstet Gynecol 2011; 54:215-218.
23. Prat J. FIGO staging for uterine sarcomas. Int J Gynaecol Obstet 2009; 104:177-178.
24. Chi DS, Mychalczak B, Saigo PE, et al. The role of whole-pelvic irradiation in the treatment of early-stage uterine carcinosarcoma. Gynecol Oncol 1997; 65:493-498. (Pubitemid 27255994)
25. Temkin SM, Hellmann M, Lee YC, Abulafia O. Early-stage carcinosarcoma of the uterus: the significance of lymph node count. Int J Gynecol Cancer 2007; 17:215-219. (Pubitemid 46213993)
26. Silverberg SG, Major FJ, Blessing JA, et al. Carcinosarcoma (malignant mixed mesodermal tumor) of the uterus. A Gynecologic Oncology Group pathologic study of 203 cases. Int J Gynecol Pathol 1990; 9:1-19. (Pubitemid 20067452)
27. Leath CA 3rd, Numnum TM, Kendrick JE 4th, et al. Patterns of failure for conservatively managed surgical stage I uterine carcinosarcoma: implications for adjuvant therapy. Int J Gynecol Cancer 2009; 19:888-891.
28. Sartori E, Bazzurini L, Gadducci A, et al. Carcinosarcoma of the uterus: a clinicopathological multicenter CTF study. Gynecol Oncol 1997; 67:70-75. (Pubitemid 27433331)
29. Yamada SD, Burger RA, Brewster WR, et al. Pathologic variables and adjuvant therapy as predictors of recurrence and survival for patients with surgically evaluated carcinosarcoma of the uterus. Cancer 2000; 88:2782-2786. (Pubitemid 30417939)
30. Nemani D, Mitra N, Guo M, Lin L. Assessing the effects of lymphadenectomy and radiation therapy in patients with uterine carcinosarcoma: a SEER analysis. Gynecol Oncol 2008; 111:82-88.
31. Vorgias G, Fotiou S. The role of lymphadenectomy in uterine carcinosarcomas (malignant mixed mullerian tumours): a critical literature review. Arch Gynecol Obstet 2010; 282:659-664.
32. Landrum LM, Moore KN, Myers TK, et al. Stage IVB endometrial cancer: does applying an ovarian cancer treatment paradigm result in similar outcomes? A case-control analysis. Gynecol Oncol 2009; 112:337-341.
33. Chi DS, Welshinger M, Venkatraman ES, Barakat RR. The role of surgical cytoreduction in stage IV endometrial carcinoma. Gynecol Oncol 1997; 67:56-60. (Pubitemid 27433329)
34. Echt G, Jepson J, Steel J, et al. Treatment of uterine sarcomas. Cancer 1990; 66:35-39. (Pubitemid 20197081)
35. Gerszten K, Faul C, Kounelis S, et al. The impact of adjuvant radiotherapy on carcinosarcoma of the uterus. Gynecol Oncol 1998; 68:8-13. (Pubitemid 28109815)
36. Wolfson AH, Brady MF, Rocereto T, et al. A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as postsurgical therapy in stage I-IV carcinosarcoma (CS) of the uterus. Gynecol Oncol 2007; 107:177-185. (Pubitemid 47575740)
37. DiSaia PJ, Castro JR, Rutledge FN. Mixed mesodermal sarcoma of the uterus. Am J Roentgenol Radium Ther Nucl Med 1973; 117:632-636.
38. Hornback NB, Omura G, Major FJ. Observations on the use of adjuvant radiation therapy in patients with stage I and II uterine sarcoma. Int J Radiat Oncol Biol Phys 1986; 12:2127-2130. (Pubitemid 17215527)
39. Larson B, Silfversward C, Nilsson B, Pettersson F. Mixed mullerian tumours of the uterus: prognostic factors-a clinical and histopathologic study of 147 cases. Radiother Oncol 1990; 17:123-132. (Pubitemid 20062407)
40. Perez CA, Askin F, Baglan RJ, et al. Effects of irradiation on mixed mullerian tumors of the uterus. Cancer 1979; 43:1274-1284. (Pubitemid 9180293)
41. Salazar OM, Bonfiglio TA, Patten SF, et al. Uterine sarcomas: analysis of failures with special emphasis on the use of adjuvant radiation therapy. Cancer 1978; 42:1161-1170. (Pubitemid 9054574)
42. Callister M, Ramondetta LM, Jhingran A, et al. Malignant mixed mullerian tumors of the uterus: analysis of patterns of failure, prognostic factors, and treatment outcome. Int J Radiat Oncol Biol Phys 2004; 58:786-796. (Pubitemid 38221136)
43. Molpus KL, Redlin-Frazier S, Reed G, et al. Postoperative pelvic irradiation in early stage uterine mixed mullerian tumors. Eur J Gynaecol Oncol 1998; 19:541-546. (Pubitemid 29008294)
44. Kohorn EI, Schwartz PE, Chambers JT, et al. Adjuvant therapy in mixed mullerian tumors of the uterus. Gynecol Oncol 1986; 23:212-221. (Pubitemid 16155037)
45. Knocke TH, Weitmann HD, Kucera H, et al. Results of primary and adjuvant radiotherapy in the treatment of mixed mullerian tumors of the corpus uteri. Gynecol Oncol 1999; 73:389-395. (Pubitemid 29272860)
46. Spanos WJ Jr, Wharton JT, Gomez L, et al. Malignant mixed mullerian tumors of the uterus. Cancer 1984; 53:311-316. (Pubitemid 14180747)
47. Reed NS, Mangioni C, Malmstrom H, et al. Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). Eur J Cancer 2008; 44:808-818.
48. Wright JD, Seshan VE, Shah M, et al. The role of radiation in improving survival for early-stage carcinosarcoma and leiomyosarcoma. Am J Obstet Gynecol 2008; 199:536e1-536e8.
49. OmuraGA, Major FJ, Blessing JA, et al. A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas. Cancer 1983; 52:626-632. (Pubitemid 13025913)
50. Muss HB, Bundy B, DiSaia PJ, et al. Treatment of recurrent or advanced uterine sarcoma. A randomized trial of doxorubicin versus doxorubicin and cyclophosphamide (a phase III trial of the Gynecologic Oncology Group). Cancer 1985; 55:1648-1653. (Pubitemid 15103908)
51. Omura GA, Blessing JA, Major F, et al. A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a Gynecologic Oncology Group Study. J Clin Oncol 1985; 3:1240-1245. (Pubitemid 15226529)
52. Sutton GP, Blessing JA, Rosenshein N, et al. Phase II trial of ifosfamide and mesna in mixed mesodermal tumors of the uterus (a Gynecologic Oncology Group study). Am J Obstet Gynecol 1989; 161:309-312. (Pubitemid 19212192)
53. Sutton G, Brunetto VL, Kilgore L, et al. A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: a Gynecologic Oncology Group Study. Gynecol Oncol 2000; 79:147-153.
54. Homesley HD, Filiaci V, Markman M, et al. Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study. J Clin Oncol 2007; 25:526-531. (Pubitemid 350002959)
55. Hoskins PJ, Le N, Ellard S, et al. Carboplatin plus paclitaxel for advanced or recurrent uterine malignant mixed mullerian tumors. The British Columbia Cancer Agency experience. Gynecol Oncol 2008; 108:58-62. (Pubitemid 350299420)
56. Lacour RA, Euscher E, Atkinson EN, et al. A phase II trial of paclitaxel and carboplatin in women with advanced or recurrent uterine carcinosarcoma. Int J Gynecol Cancer 2011; 21:517-522.
57. Powell MA, Filiaci VL, Rose PG, et al. Phase II evaluation of paclitaxel and carboplatin in the treatment of carcinosarcoma of the uterus: a Gynecologic Oncology Group study. J Clin Oncol 2010; 28:2727-2731.
58. Wong L, See HT, Khoo-Tan HS, et al. Combined adjuvant cisplatin and ifosfamide chemotherapy and radiotherapy for malignant mixed mullerian tumors of the uterus. Int J Gynecol Cancer 2006; 16:1364-1369. (Pubitemid 43886770)
59. Manolitsas TP, Wain GV, Williams KE, et al. Multimodality therapy for patients with clinical stage I and II malignant mixed Mullerian tumors of the uterus. Cancer 2001; 91:1437-1443. (Pubitemid 32319253)
60. Menczer J, Levy T, Piura B, et al. A comparison between different postoperative treatment modalities of uterine carcinosarcoma. Gynecol Oncol 2005; 97:166-170. (Pubitemid 40403689)
61. Makker V, Abu-Rustum NR, Alektiar KM, et al. A retrospective assessment of outcomes of chemotherapy-based versus radiation-only adjuvant treatment for completely resected stage I-IV uterine carcinosarcoma. Gynecol Oncol 2008; 111:249-254.
62. Miller DS, Blessing JA, Schilder J, et al. Phase II evaluation of topotecan in carcinosarcoma of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol 2005; 98:217-221. (Pubitemid 41019108)
63. Miller BE, Blessing JA, Stehman FB, et al. A phase II evaluation of weekly gemcitabine and docetaxel for second-line treatment of recurrent carcinosarcoma of the uterus: a gynecologic oncology group study. Gynecol Oncol 2010; 118:139-144.